Last reviewed · How we verify
Florafur (TEGAFUR)
Florafur (generic name: TEGAFUR) is a tegafur Small molecule drug developed by Nordic Group BV. It is currently FDA-approved for HER2negative breast cancer, Hormone receptor pozitive breast cancer, Malignant tumor of stomach.
Florafur is a small molecule used in the treatment of various cancers, including locally advanced gastric adenocarcinoma, nasopharyngeal carcinoma, and breast cancer. It is often administered in combination with other treatments, such as docetaxel and S-1 (Tegafur-Gimeracil-Oteracil), as part of adjuvant therapy.
At a glance
| Generic name | TEGAFUR |
|---|---|
| Sponsor | Nordic Group BV |
| Drug class | tegafur |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- HER2negative breast cancer
- Hormone receptor pozitive breast cancer
- Malignant tumor of stomach
Common side effects
Key clinical trials
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE4)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (PHASE2)
- Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer (PHASE3)
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer (PHASE1)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Florafur CI brief — competitive landscape report
- Florafur updates RSS · CI watch RSS
- Nordic Group BV portfolio CI
Frequently asked questions about Florafur
What is Florafur?
What is Florafur used for?
Who makes Florafur?
What is the generic name of Florafur?
What drug class is Florafur in?
What development phase is Florafur in?
Related
- Drug class: All tegafur drugs
- Manufacturer: Nordic Group BV — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2negative breast cancer
- Indication: Drugs for Hormone receptor pozitive breast cancer
- Indication: Drugs for Malignant tumor of stomach